Marie Lundberg1, Suvi Renkonen1,2, Caj Haglund3,4,5, Petri S Mattila1, Ilmo Leivo6, Jaana Hagström3, Antti A Mäkitie1,2. 1. a Department of Otorhinolaryngology - Head and Neck Surgery , University of Helsinki and Helsinki University Hospital , Helsinki , Finland ; 2. b Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences , Intervention and Technology, Karolinska Institutet and Karolinska Hospital , Stockholm , Sweden ; 3. c Department of Pathology, Haartman Institute and HusLab , University of Helsinki and Helsinki University Hospital , Helsinki , Finland ; 4. d Department of Surgery , University of Helsinki and Helsinki University Hospital , Helsinki , Finland ; 5. e Research Programs Unit, Translational Cancer Biology, University of Helsinki , Helsinki , Finland ; 6. f Department of Pathology , Turku University Hospital and University of Turku , Turku , Finland.
Abstract
CONCLUSIONS: BMI-1 is an upstream repressor of tumor suppressor p16 and their inverse expression patterns have been linked with patient survival in OPSCC. In this material only p16 remained a relevant prognostic marker in OPSCC. OBJECTIVES: HNSCC tumors carry variable phenotypes and clinical outcomes depending on their anatomical location. In OPSCC, expression of tumor suppressor p16 is used as a surrogate marker of HPV infection and has prognostic value. There are no good prognostic biomarkers for HNSCC tumors of other anatomical locations. AIM: To study the expression patterns of p16 and BMI-1 in not only oropharyngeal but also oral, hypopharyngeal, and laryngeal squamous cell carcinomas and to clarify their putative connections with clinical parameters, survival, and each other. METHOD: Hospital records on 130 patients (59 OPSCC, 18 OSCC, 20 HPSCC, and 33 LSCC) diagnosed between 1997-2008 at the Helsinki University Hospital, Finland, were reviewed. BMI-1 and p16 expressions were studied by immunohistochemistry. RESULTS: Sixty-eight per cent of OPSCC expressed p16 and expression correlated with lower age, lower T- and higher N-category, and with improved OS and DFS. BMI-1 expression was most prevalent in OPSCC and LSCC, but had no clinical correlations. No correlation between p16 and BMI-1 expression was found.
CONCLUSIONS:BMI-1 is an upstream repressor of tumor suppressor p16 and their inverse expression patterns have been linked with patient survival in OPSCC. In this material only p16 remained a relevant prognostic marker in OPSCC. OBJECTIVES:HNSCC tumors carry variable phenotypes and clinical outcomes depending on their anatomical location. In OPSCC, expression of tumor suppressor p16 is used as a surrogate marker of HPV infection and has prognostic value. There are no good prognostic biomarkers for HNSCC tumors of other anatomical locations. AIM: To study the expression patterns of p16 and BMI-1 in not only oropharyngeal but also oral, hypopharyngeal, and laryngeal squamous cell carcinomas and to clarify their putative connections with clinical parameters, survival, and each other. METHOD: Hospital records on 130 patients (59 OPSCC, 18 OSCC, 20 HPSCC, and 33 LSCC) diagnosed between 1997-2008 at the Helsinki University Hospital, Finland, were reviewed. BMI-1 and p16 expressions were studied by immunohistochemistry. RESULTS: Sixty-eight per cent of OPSCC expressed p16 and expression correlated with lower age, lower T- and higher N-category, and with improved OS and DFS. BMI-1 expression was most prevalent in OPSCC and LSCC, but had no clinical correlations. No correlation between p16 and BMI-1 expression was found.
Authors: Mark Jakob; Kariem Sharaf; Markus Schirmer; Martin Leu; Stefan Küffer; Mattis Bertlich; Friedrich Ihler; Frank Haubner; Martin Canis; Julia Kitz Journal: Strahlenther Onkol Date: 2020-06-25 Impact factor: 3.621
Authors: Steven F Gameiro; Bart Kolendowski; Ali Zhang; John W Barrett; Anthony C Nichols; Joe Torchia; Joe S Mymryk Journal: Oncotarget Date: 2017-08-03
Authors: Kariem Sharaf; Axel Lechner; Stefan P Haider; Robert Wiebringhaus; Christoph Walz; Gisela Kranz; Martin Canis; Frank Haubner; Olivier Gires; Philipp Baumeister Journal: Curr Oncol Date: 2021-07-19 Impact factor: 3.677